Marcy l’Étoile, France - 19 mai 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures (cf. press release of April 12th).
bioMérieux acquired 100% ownership of Specific Diagnostics for an acquisition price equivalent to 3.2% of bioMérieux market capitalization as of May 18, 2022. The acquisition price has been paid with a combination of cash and shares issued to certain Specific Diagnostics shareholders. The issuance of 1.288.901 new bioMérieux shares shall result in a share dilution of approximately 1% of the share capital. bioMérieux will soon launch a share buyback program to offset this share dilution over time.
Thanks to this acquisition, bioMérieux expects to further develop its global leadership in clinical microbiology, bringing major innovation to the market and further strengthening its fight against Antimicrobial Resistance.